In conclusion, CXCR4 is a promising independent prognostic marker for R-CHOP-treated DLBCL patients, possibly due to inverse correlation between CXCR4 expression and rituximab sensitivity. This evidence concerns the gene CXCR4 and diffuse large B-cell lymphoma.